HCM Screening Yield (Community Athlete) Calculator

Clinical calculation support · Verify results before clinical use

Screening inputs

Use locally appropriate prevalence and test-performance estimates.

Yield model
Total number of community athletes expected to be screened. Enter a whole number.
Enter prevalence as a percentage, not a proportion. For example, 0.2 means 0.2% (approximately 1 in 500).
%
Proportion of athletes with HCM correctly identified by the screening ECG. Estimates depend on the population and ECG interpretation criteria.
%
Proportion of athletes without HCM correctly classified as screen-negative.
%
Reset calculator

About this screening model

This calculator combines assumed HCM prevalence with the sensitivity and specificity of an ECG-based screening strategy to estimate expected screening outcomes in a defined cohort.

How the model works

  • Expected HCM cases = cohort size × prevalence.
  • True positives = expected HCM cases × sensitivity.
  • False negatives = expected HCM cases − true positives.
  • True negatives = expected non-cases × specificity.
  • False positives = expected non-cases − true negatives.
  • PPV = TP / (TP + FP); NPV = TN / (TN + FN).
  • Yield per 1,000 = TP / cohort size × 1,000; NNS = cohort size / TP.

Choosing assumptions

Important about the prefilled values: the initial sensitivity (93%) and specificity (96%) are illustrative starting assumptions only; they are not universally validated HCM-specific estimates. Replace them with estimates appropriate to the population and screening pathway being evaluated.

Use prevalence and test-performance estimates appropriate to the age, athletic population, ECG interpretation criteria, and downstream diagnostic pathway being evaluated. A commonly cited estimate of approximately 1 in 500 refers to unexplained asymptomatic hypertrophy in young adults in the United States; it should not automatically be treated as the prevalence of confirmed HCM in every community athlete cohort.

Evidence reporting performance of ECG screening for a composite of potentially lethal cardiovascular disorders does not necessarily provide HCM-specific sensitivity and specificity. Enter locally justified estimates where available and perform sensitivity analyses when uncertainty is substantial.

Clinical context & limitations

ECG screening may identify electrical or structural-disease patterns that warrant further evaluation, but a screening ECG is not a definitive diagnostic test for HCM.

  • Results depend strongly on the assumed prevalence, sensitivity, and specificity.
  • False-positive screens require appropriate secondary assessment; this model does not estimate cost, access, or downstream testing burden.
  • A normal ECG does not exclude all HCM or other causes of sudden cardiac arrest in athletes.
  • The model does not include age-specific prevalence, repeated screening, competing diagnoses, incomplete follow-up, or time-to-diagnosis.
  • Do not use these estimates alone to determine sports eligibility or individual clinical management.

Selected references

Ommen SR, et al.2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy. Circulation. 2024. doi:10.1161/CIR.0000000000001250.
Harmon KG, et al.The effectiveness of screening history, physical exam, and ECG to detect potentially lethal cardiac disorders in athletes: a systematic review/meta-analysis. J Electrocardiol. 2015. PubMed: 25701104. Results concern potentially lethal cardiovascular conditions collectively, not HCM alone.
Sharma S, et al.International criteria for electrocardiographic interpretation in athletes: consensus statement. Br J Sports Med. 2017;51:704–731. Read consensus statement.
AHA/ACC Scientific Statement.Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities. J Am Coll Cardiol. 2025. Read scientific statement.
Clinical disclaimer: This calculator is an educational planning model, not a validated diagnostic or prognostic instrument. Its outputs are only as reliable as the input assumptions. Use current evidence, local epidemiology, appropriate clinical assessment, and shared decision-making when designing or interpreting athlete screening programs.